Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in <i>KRAS</i> Wild-Type Patients

<table>A panel of different genes will be a step forward in the “personalized medicine” of CRC patients for selecting patients and predicting efficacy of anti-EGFR therapy.<i> KRAS</i> WT: no mutations were detected in exons 2, 3, and 4.</table>

BioMed Research International

fig3

Figure 3

Figure 3: Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in <i>KRAS</i> Wild-Type Patients 

BioMed Research International

Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients

Figure 3